Dr. Douglas Loe

Leede Financial Inc.

Recent Articles

Biotech Advancing Pivotal Phase III Breast Cancer Trial 03/11/2025

Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc.

FDA OKs Trial of Cell Reservoir in Thyroid Disease 03/10/2025

In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.

Canadian Healthcare Co. Showcases Stable FQ424 03/06/2025

Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.

Kentucky Medical Co. Has Strong Operating Fundamentals 02/12/2025

Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note.

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease 02/04/2025

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company.

Medical Equipment Co. Shows Strong Profit Margin 12/20/2024

Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report.

FDA Decision on Drug for Bone Marrow Due Early 2025 12/06/2024

The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report.

Developer of Medical Instruments Attracts Research Coverage 12/02/2024

Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report.

Analyst Says Biotech's Data Supports Advancement Into Phase III 11/19/2024

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.

Opportunity Arises for Co. With Cell Pouch 11/12/2024

This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.

Medical Co. Ready for a Transformative F2025 11/05/2024

The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates.

Biotech Shares Positive Phase I Data for Alzheimer's Treatment 10/31/2024

Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.

Co's. Cell Pouch Performs Well in Study 09/16/2024

Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.

Long Term Care Co.'s Target Price Raised 08/14/2024

Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results.

Biopharma Co. Reports Strong FQ224 Results Driven 07/11/2024

Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).

Analyst Encouraged by ON Gov's Decision To Sustain Fees 04/02/2024

CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.

Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says 03/26/2024

K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.